Zevra Therapeutics stock price target lowered to $18 at Citizens JMP

Investing.com - Citizens JMP lowered its price target on Zevra Therapeutics, Inc. (NASDAQ:ZVRA) to $18.00 from $19.00 on Wednesday while maintaining a Market Outperform rating. According to InvestingPro data, the stock has delivered an impressive 73.45% return over the past year, with analyst targets ranging from $19 to $29.

The firm adjusted its target following Zevra’s second-quarter 2025 financial results, which showed MIPLYFFA sales of $21.5 million, exceeding both Citizens JMP and consensus estimates of approximately $20 million. The company’s overall revenue growth stands at 46.47%, with InvestingPro analysis indicating strong sales growth potential ahead.

Citizens JMP noted the MIPLYFFA launch continues to outperform expectations, with 129 total patient enrollment forms received to date, representing an increase of 7 from the 122 reported at the end of March.

The research firm increased its MIPLYFFA projections for the second half of 2025 and beyond, while simultaneously lowering estimates for OLPRUVA, which continues to face market headwinds.

Zevra ended the second quarter with approximately $218 million in cash, which Citizens JMP believes positions the company well to achieve positive cash flow.

In other recent news, Zevra Therapeutics released its Q2 2025 earnings report, showcasing a mixed financial outcome. The company reported an earnings per share (EPS) of -$0.06, falling short of the projected $2.19. On a positive note, Zevra Therapeutics achieved a revenue of $25.9 million, exceeding expectations by 15.16%. This revenue performance indicates the company’s ability to generate more income than anticipated. Despite the EPS miss, the revenue beat may have contributed to investor optimism. Analysts and investors might be focusing on the revenue growth as a sign of strategic progress. These developments reflect the company’s recent financial activities and market responses.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.